birch allergen
Allergenapproved
Clinical trial activity
41 trials · 41 clinical orgs · 1 marketing orgs
Phase 1
5
Phase 2
25
Phase 3
13
Phase 4
3
Earliest trial started Nov 1, 2002 (NCT00410930)
Timeline
Indications
Approved for
Mechanism of action
- Tree pollenImmunity, desensitized
Tree pollen immunity, desensitized
Approval history
- approved—
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- birch allergen
- birch polle
- birch pollen
- birch pollen allergen
- birch pollen allergen extract
- birch pollen extract
- birch tree allergen
- depigoid birch
- depiquick birch
- purethal birch
- sublivac fix birch
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05346718 | N/A | Sep 30, 2022 | Fraunhofer, University of California, Irvine |
| NCT04813380 | Phase 3 | Jul 27, 2021 | Zagazig University |
| NCT04851860 | Phase 3 | Apr 12, 2021 | Zagazig University |
| NCT04296474 | Phase 1/Phase 2 (Phase 2) | May 15, 2018 | Karolinska Institute |
| NCT04641130 | N/A | Jul 13, 2017 | Alyatec |
| NCT03375775 | N/A | May 1, 2017 | Karolinska Institute |
| NCT02943720 | Phase 2 | Sep 1, 2016 | Anergis, University of London |
| NCT02478060 | Phase 2 | Jul 1, 2015 | Adiga Life Sciences, Inc., Circassia Limited, IQVIA |
| NCT02481856 | Phase 2 | Jun 1, 2015 | ALK-Abello, S.A., Inflamax |
| NCT02679105 | Phase 2/Phase 3 (Phase 3) | May 1, 2015 | Karolinska Institute, Lund University, Sodra Alvsborgs Hospital |
| NCT02351830 | N/A | Jan 31, 2015 | Queen's University, Belfast, University of British Columbia |
| NCT02271009 | Phase 2 | Oct 1, 2014 | Anergis, Inflamax |
| NCT02231307 | Phase 3 | Sep 1, 2014 | HAL Allergy |
| NCT02146300 | N/A | Mar 1, 2014 | University of Oslo, University of Oulu |
| NCT03157505 | Phase 3 | Jan 5, 2014 | Silesian University of Medicine |
| NCT01983865 | N/A | Nov 30, 2013 | Fraunhofer |
| NCT01918956 | Phase 4 | Sep 1, 2013 | Ergomed, HAL Allergy, NZOZ Centrum Alergologii |
| NCT01720251 | Phase 2 | Oct 1, 2012 | Anergis, University of Lausanne |
| NCT01694836 | Phase 3 | Sep 1, 2012 | Leti Pharma GmbH |
| NCT01431859 | Phase 4 | Jul 1, 2012 | University of Brighton, University of Sussex |
Showing 20 of 41 trials
Page 1 / 3
Organizations
Research & Development (41)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Allergopharma GmbH & Co. KG | For profit | 5 | 5 | 2 | 2003 |
| Anergis | For profit | 5 | 5 | 2 | 2008 |
| HAL Allergy | For profit | 4 | 4 | 3 | 2009 |
| Karolinska Institute | Academic/Hospital | 4 | 4 | 3 | 2010 |
| University of Lausanne | Academic/Hospital | 3 | 0 | 2 | 2008 |
| ALK-Abello, S.A. | For profit | 2 | 2 | 2 | 2005 |
| Fraunhofer | For profit | 2 | 2 | 1 | 2013 |
| Humboldt University | Academic/Hospital | 2 | 0 | 2 | 2005 |
| Inflamax | For profit | 2 | 0 | 1 | 2014 |
| IQVIA | For profit | 2 | 0 | 2 | 2010 |
| Leti Pharma GmbH | For profit | 2 | 2 | 2 | 2010 |
| Lund University | Academic/Hospital | 2 | 0 | 1 | 2010 |
| Stallergenes | For profit | 2 | 2 | 2 | 2002 |
| University of Sussex | Academic/Hospital | 2 | 2 | 2 | 2012 |
| University of Vienna | Academic/Hospital | 2 | 2 | 2 | 2011 |
| Zagazig University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Adiga Life Sciences, Inc. | For profit | 1 | 0 | 1 | 2015 |
| Alyatec | For profit | 1 | 1 | 1 | 2017 |
| Aptuit Inc. | For profit | 1 | 0 | 1 | 2010 |
| Austrian Science Fund (FWF) | Government | 1 | 0 | 1 | 2012 |
41 organizations
Page 1 / 3
Marketing (1)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Chiesi | For profit | NDA | Dec 18, 2023 |